Lutathera for high-grade brain tumors that returned or got worse
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a high-grade brain tumor (WHO grade III-IV) or a meningioma that has come back or is growing.
- You must be between 4 and 39 years old when you join.
- Your tumor must show uptake on a special PET scan called DOTATATE, meaning it has a target for Lutathera.
- You must have recovered from side effects of previous treatments, with at least 21 days since last chemotherapy or 7 days since last biologic drug.
- Your brain function (performance status) must be at least 50%, meaning you can do most daily activities with some help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.